Larotrectinib - Array BioPharma/Loxo Oncology

Drug Profile

Larotrectinib - Array BioPharma/Loxo Oncology

Alternative Names: ARRY 470; LOXO-101

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Loxo Oncology; National Cancer Institute (USA)
  • Class Antineoplastics; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Solid tumours; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Histiocytosis; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I/II CNS cancer
  • Preclinical Acute lymphoblastic leukaemia

Most Recent Events

  • 18 Oct 2017 Updated pooled efficacy data from a phase I trial, phase II NAVIGATE and phase I/II SCOUT trial in Solid tumours released by Loxo Oncology
  • 08 Aug 2017 Loxo Oncology announces intention to submit a New Drug Application (NDA) for larotrectinib to the FDA for Solid tumours in late 2017 or early 2018
  • 04 Aug 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top